Dr Han presents results at the San Antonio Breast Cancer Symposium 2016 from a randomised phase II study of veliparib against placebo in combination with carboplatin and paclitaxel, for patients with locally recurrent of metastatic BRCA1/2 mutated breast cancer.

The data presented at this press conference reflects two arms of a three arm study, with the veliparib plus temozolomide results not yet available.

Dr Han describes the addition of veliparib as well tolerated, with similar toxicity profile to the placebo arm, and notes an improvement in partial r response rate, though clinical benefit and duration of response was equivalent to placebo.